Shenyan Kangfu Pian II clinical trial program (Research 1): Evaluation of the Shenyan Kangfu Pian in the treatment of diabetic nephropathy (Qi Deficiency) safety and effectiveness of the randomized, double-blind, placebo-controlled, multicenter clinical study

Shenyan Kangfu Pian II clinical trial program (Research 1): Evaluation of the Shenyan kangfu Pian in the treatment of diabetic nephropathy (Qi deficiency): a randomized, double blinding, placebo controlled multicenter clinical study

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12002182

Enrollment

Unknown

Registered

2012-05-17

Start date

2012-05-14

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic nephropathy

Interventions

Experimental group:Shenyan Kangfu Pian +Irbesartan Tablets

Control group:Simulant byShenyan Kangfu Pian +Irbesartan Tablets

Eligibility

Sex/Gender

All

Age

35 Years to 65 Years

Inclusion criteria

Inclusion criteria: Compliance with diabetic nephropathy (III of IV period) Western diagnostic criteria;Comply with the Qi and Yin Deficiency type TCM standards;The age of 35 to 65 years of age;The patients or guardians informed consent and signed the informed consent volunteer subjects.

Exclusion criteria

Exclusion criteria: Glycated hemoglobin (HbA1c) greater than 59mmol/L. 24-hour urine protein greater than 3g, serum albumin (ALB) is less than 25g/L, glomerular filtration rate (GFR) <60ml/min who. Serious diseases are of primary cardiovascular disease, liver disease, hematological disease, lung disease or influence their survival. The drug with known experimental drug allergy (including non-allergic but the recent use of the drug), or drug allergies, and allergic constitution. Pregnancy in preparation for pregnancy, and lactating women.

Design outcomes

Primary

Measure	Time frame
Urine albumin / urine creatinine;24-hour urinary protein excretion;Urinary albumin excretion rate;	—

Countries

China

Contacts

Public ContactDeng Yueyi

Shanghai University of Traditional Chinese Medicine, Longhua Hospital

dengyueyi@medmail.com.cn+86 13331812359

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026